Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
HEXALEN |
| Manufacturer |
|
MGI Pharma, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
S-triazine derivative. |
| Generic Name |
|
Altretamine 50mg; caps. |
| Indications |
|
Palliative treatment of persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination. |
| Children |
|
Not recommended. |
| Adults |
|
260mg/m2 daily in four divided doses (after meals and at bedtime), for either 14 or 21 consecutive days in a 28-day cycle. Discontinue for >14 days if GI intolerance is unresponsive to treatment, WBC count <2000/mm3 or granulocyte count <1000/mm3, platelet count <75000/mm3, or progressive neurotoxicity occurs. Restart at 200mg/m2 daily. Discontinue indefinitely if neurologic symptoms fail to stabilize. |
| Contraindications |
|
Severe myelosuppression or neurologic toxicity, except cisplatin-related neuropathy. |
| Precautions |
|
Monitor for myelosuppression (do monthly CBCs) and neurotoxicity. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Avoid pyridoxine. Severe orthostatic hypotension with MAOIs. |
| Adverse Reactions |
|
Nausea, vomiting, peripheral neuropathy, CNS symptoms (eg, mood disorders, ataxia, dizziness), myelosuppression, renal dysfunction, increased alkaline phosphatase. |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
